{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:57:23Z","timestamp":1792425443484,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Soft-tissue sarcomas are rare, diverse malignant tumors of mesenchymal origin, requiring diagnosis and treatment by a specialized multidisciplinary team. Initial assessment includes radiology and biopsy, followed by wide surgical resection with clear margins for localized cases. Radiotherapy is recommended for large, deep, high-grade tumors or after incomplete resection, while perioperative chemotherapy may be considered for high-risk cases. In oligometastatic disease, combining local and systemic therapies is an option. Anthracycline-based chemotherapy is the first-line treatment in advanced disease, though other drugs show efficacy in certain subtypes. Given the\u00a0limited options, enrolling in clinical trials is advised for patients needing further treatment.<\/jats:p>","DOI":"10.1007\/s12094-024-03842-5","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T10:48:21Z","timestamp":1738925301000},"page":"1460-1471","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["SEOM-GEIS Spanish clinical guidelines for the management of soft\u2011tissue sarcomas (2024)"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1416-8739","authenticated-orcid":false,"given":"C\u00e9sar","family":"Serrano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Arregui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Hindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Mart\u00ednez-Trufero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jer\u00f3nimo","family":"Mart\u00ednez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1urea","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Pais\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"Sala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"3842_CR1","unstructured":"Fletcher C, Bridge JA, Antonescu C, Mertens F (eds). WHO Classification of Tumours: Soft Tissue and Bone Tumours, 5th edn. Vol 3. April 2020."},{"issue":"6629","key":"3842_CR2","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1126\/science.abj4784","volume":"379","author":"ML Ballinger","year":"2023","unstructured":"Ballinger ML, Pattnaik S, Mundra PA, Zaheed M, Rath E, Priestley P, et al. Heritable defects in telomere and mitotic function selectively predispose to sarcomas. Science. 2023;379(6629):253\u201360.","journal-title":"Science"},{"issue":"12","key":"3842_CR3","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1200\/JCO.2009.25.1728","volume":"28","author":"RA Gladdy","year":"2010","unstructured":"Gladdy RA, Qin LX, Moraco N, Edgar MA, Antonescu CR, Alektiar KM, et al. Do radiation-associated soft tissue sarcomas have the same prognosis as sporadic soft tissue sarcomas? J Clin Oncol. 2010;28(12):2064\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3842_CR4","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1093\/clinids\/18.3.421","volume":"18","author":"PA Gross","year":"1994","unstructured":"Gross PA, Barrett TL, Dellinger EP, Krause PJ, Martone WJ, McGowan JE, et al. Purpose of quality standards for infectious diseases. Clin Infect Dis. 1994;18(3):421\u20136.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"3842_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/ijc.2910330108","volume":"33","author":"M Trojani","year":"1984","unstructured":"Trojani M, Contesso G, Coindre JM, Rouesse J, Bui NB, de Mascarel A, et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer. 1984;33(1):37\u201342.","journal-title":"Int J Cancer"},{"issue":"4","key":"3842_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.annonc.2024.01.001","volume":"35","author":"JY Blay","year":"2024","unstructured":"Blay JY, Penel N, Valentin T, Anract P, Duffaud F, Dufresne A, et al. Improved nationwide survival of sarcoma patients with a network of reference centers. Ann Oncol. 2024;35(4):351\u201363.","journal-title":"Ann Oncol"},{"key":"3842_CR7","doi-asserted-by":"crossref","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C (eds). TNM Classification of Malignant Tumours, 8th edn. Oxford: John Wiley & Sons, Inc. 2016.","DOI":"10.1002\/9780471420194.tnmc26.pub3"},{"issue":"5","key":"3842_CR8","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(16)00010-3","volume":"17","author":"D Callegaro","year":"2016","unstructured":"Callegaro D, Miceli R, Bonvalot S, Ferguson P, Strauss DC, Levy A, et al. Development and external validation of two nomograms to predict overall survival and occurence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. Lancet Oncol. 2016;17(5):671\u201380.","journal-title":"Lancet Oncol"},{"issue":"5","key":"3842_CR9","first-page":"526","volume":"24","author":"FR Eilber","year":"1997","unstructured":"Eilber FR, Eckardt J. Surgical management of soft tissue sarcomas. Semin Oncol. 1997;24(5):526.","journal-title":"Semin Oncol"},{"key":"3842_CR10","doi-asserted-by":"crossref","unstructured":"Deroose JP, Eggermont AM, van Geel An, Burger JW, den Bakker MA, de Wilt JH, et al. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcoma. J Clin Oncol. 2011;29(30):4036\u201344.","DOI":"10.1200\/JCO.2011.35.6618"},{"issue":"8","key":"3842_CR11","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1245\/s10434-014-3732-4","volume":"21","author":"JD Beane","year":"2014","unstructured":"Beane JD, Yang JC, White D, Steinberg SM, Rosenberg SA, Rudloff U. Efficacy of adjuvant radiation therapy in the treatment of soft tissue sarcoma of the extremity: 20-year follow up of a randomized prospective trial. Ann Surg Oncol. 2014;21(8):2484\u20139.","journal-title":"Ann Surg Oncol"},{"issue":"9325","key":"3842_CR12","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1016\/S0140-6736(02)09292-9","volume":"359","author":"B O\u2019Sullivan","year":"2002","unstructured":"O\u2019Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002;359(9325):2235\u201341.","journal-title":"Lancet"},{"issue":"10","key":"3842_CR13","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1002\/cncr.27951","volume":"119","author":"B O\u2019Sullivan","year":"2013","unstructured":"O\u2019Sullivan B, Griffin AM, Dickie CI, Sharpe MB, Chung PW, Catton CN, et al. Phase 2 study of preoperative image-guided intensity-modulated radiation therapy to reduce wound and combined modality morbidities in lower extremity soft tissue sarcoma. Cancer. 2013;119(10):1878\u201384.","journal-title":"Cancer"},{"issue":"31","key":"3842_CR14","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1200\/JCO.2015.62.9394","volume":"33","author":"E Palassini","year":"2015","unstructured":"Palassini E, Ferrari S, Verderio P, et al. Feasibility of preoperative chemotherapy with or without radiation therapy in localized soft tissue sarcomas of limbs and superficial trunk in the Italian Sarcoma Group\/Grupo Espa\u00f1ol de Investigaci\u00f3n en Sarcomas randomized clinical trial: three versus five cycles of full-dose epirubicin plus ifosfamide. J Clin Oncol. 2015;33(31):3628\u201334.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3842_CR15","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1200\/JCO.2001.19.5.1238","volume":"19","author":"S Frustaci","year":"2001","unstructured":"Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19(5):1238\u201347.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3842_CR16","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/cncr.23592","volume":"113","author":"N Pervaiz","year":"2008","unstructured":"Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573\u201381.","journal-title":"Cancer"},{"issue":"12","key":"3842_CR17","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1093\/annonc\/mdw430","volume":"27","author":"A Gronchi","year":"2016","unstructured":"Gronchi A, Stacchiotti S, Verderio P, Ferrari S, Martin Broto J, Lopez-Pousa A, et al. Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. Ann Oncol. 2016;27(12):2283\u20138.","journal-title":"Ann Oncol"},{"key":"3842_CR18","doi-asserted-by":"crossref","unstructured":"Gronchi A, Palmerini E, Quagliuolo V, Martin-Broto J, Lopez-Pousa, Grignani G, et al. Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. J Clin Oncol. 2020;38(19):2178\u201386.","DOI":"10.1200\/JCO.19.03289"},{"issue":"4","key":"3842_CR19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1001\/jamaoncol.2017.4996","volume":"4","author":"RD Issels","year":"2018","unstructured":"Issels RD, Lindner LH, Verweij J, Wessalowski R, Reichardt P, Wust P, et al. Effect of neoadjuvant chemo- therapy plus regional hyperthermia on long-term outcomes among patients with localized high-risk soft tissue sarcoma: the EORTC 62961- ESHO 95 randomized clinical trial. JAMA Oncol. 2018;4(4):483\u201392.","journal-title":"JAMA Oncol"},{"issue":"1","key":"3842_CR20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/cncr.33895","volume":"128","author":"S Pasquali","year":"2022","unstructured":"Pasquali S, Palmerii E, Quagliuolo V, Martin-Broto J, Lopez-Pousa A, Grignani G, et al. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial. Cancer. 2022;128(1):85\u201393.","journal-title":"Cancer"},{"issue":"13","key":"3842_CR21","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2020.1707","volume":"323","author":"WD Tap","year":"2020","unstructured":"Tap WD, Wagner AJ, Sch\u00f6ffski P, et al. Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: the ANNOUNCE randomized clinical trial. JAMA. 2020;323(13):1266\u201376.","journal-title":"JAMA"},{"issue":"2","key":"3842_CR22","doi-asserted-by":"publisher","first-page":"100425","DOI":"10.1016\/j.esmoop.2022.100425","volume":"7","author":"EF Nassif","year":"2022","unstructured":"Nassif EF, Blay JY, Massard C, et al. Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials. ESMO Open. 2022;7(2):100425.","journal-title":"ESMO Open"},{"issue":"10","key":"3842_CR23","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1016\/0277-5379(87)90089-7","volume":"23","author":"HT Mouridsen","year":"1987","unstructured":"Mouridsen HT, Bastholt L, Somers R, Santoro A, Bramwell V, Mulder JH, et al. Adriamycin versus epirubicin in advanced soft tissue sarcomas A randomized phase II\/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol. 1987;23(10):1477\u201383.","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"4","key":"3842_CR24","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","volume":"15","author":"I Judson","year":"2014","unstructured":"Judson I, Verweij J, Gelderblom H, Hartmann JT, Schoffski P, Blay JY, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15(4):415\u201323.","journal-title":"Lancet Oncol"},{"issue":"8","key":"3842_CR25","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/S1470-2045(22)00380-1","volume":"23","author":"P Pautier","year":"2022","unstructured":"Pautier P, Italiano A, Piperno-Neumann S, Chevreau C, Penel N, Firmin N, et al. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol. 2022;23(8):1044\u201354.","journal-title":"Lancet Oncol"},{"issue":"11","key":"3842_CR26","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1002\/cncr.32795","volume":"126","author":"L D'Ambrosio","year":"2020","unstructured":"D\u2019Ambrosio L, Touati N, Blay JY, Grignani G, Flippot R, Czarnecka AM, et al. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Cancer. 2020;126(11):2637\u201347.","journal-title":"Cancer"},{"issue":"10","key":"3842_CR27","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S1470-2045(17)30622-8","volume":"18","author":"B Seddon","year":"2017","unstructured":"Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017;18(10):1397\u2013410.","journal-title":"Lancet Oncol"},{"issue":"1","key":"3842_CR28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0959-8049(99)00240-3","volume":"36","author":"OS Nielsen","year":"2000","unstructured":"Nielsen OS, Judson I, van Hoesel Q, le Cesne A, Keizer HJ, Blay JY, et al. Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2000;36(1):61\u20137.","journal-title":"Eur J Cancer"},{"issue":"32","key":"3842_CR29","doi-asserted-by":"publisher","first-page":"5269","DOI":"10.1200\/JCO.2008.17.3146","volume":"26","author":"N Penel","year":"2008","unstructured":"Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008;26(32):5269\u201374.","journal-title":"J Clin Oncol"},{"issue":"30","key":"3842_CR30","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1200\/JCO.20.00714","volume":"38","author":"V Gr\u00fcnwald","year":"2020","unstructured":"Gr\u00fcnwald V, Karch A, Schuler M, et al. Randomized comparison of pazopanib and doxorubicin as first-line treatment in patients with metastatic soft tissue sarcoma age 60 years or older: results of a German intergroup study. J Clin Oncol. 2020;38(30):3555\u201364.","journal-title":"J Clin Oncol"},{"issue":"7","key":"3842_CR31","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1200\/JCO.1995.13.7.1600","volume":"13","author":"A Le Cesne","year":"1995","unstructured":"Le Cesne A, Antoine E, Spielmann M, et al. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol. 1995;13(7):1600\u20138.","journal-title":"J Clin Oncol"},{"issue":"18","key":"3842_CR32","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1200\/JCO.2010.33.6107","volume":"29","author":"X Garc\u00eda-Del-Muro","year":"2011","unstructured":"Garc\u00eda-Del-Muro X, L\u00f3pez-Pousa A, Maurel J, Mart\u00edn J, Mart\u00ednez-Trufero J, Casado A, et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol. 2011;29(18):2528\u201333.","journal-title":"J Clin Oncol"},{"issue":"19","key":"3842_CR33","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1200\/JCO.2006.10.4117","volume":"25","author":"RG Maki","year":"2007","unstructured":"Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol. 2007;25(19):2755\u201363.","journal-title":"J Clin Oncol"},{"issue":"8","key":"3842_CR34","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","volume":"34","author":"GD Demetri","year":"2016","unstructured":"Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, et al. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol. 2016;34(8):786\u201393.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3842_CR35","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1001\/jamaoncol.2019.6584","volume":"6","author":"J Martin-Broto","year":"2020","unstructured":"Martin-Broto J, Hindi N, Lopez-Pousa A, Peinado-Serrano J, Alvarez R, Alvarez-Gonzalez A, et al. Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas: A Nonrandomized Phase 1\/2 Clinical Trial. JAMA Oncol. 2020;6(4):535\u201341.","journal-title":"JAMA Oncol"},{"issue":"9829","key":"3842_CR36","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","volume":"379","author":"WT van der Graaf","year":"2012","unstructured":"van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879\u201386.","journal-title":"Lancet"},{"issue":"10028","key":"3842_CR37","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","volume":"387","author":"P Sch\u00f6ffski","year":"2016","unstructured":"Sch\u00f6ffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016;387(10028):1629\u201337.","journal-title":"Lancet"},{"issue":"4","key":"3842_CR38","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.21037\/jtd-2019-pm-13","volume":"13","author":"D Stamenovic","year":"2021","unstructured":"Stamenovic D, Hohenberger P, Roessner E. Pulmonary metastasectomy in soft tissue sarcomas: a systematic Review. J Thorac Dis. 2021;13(4):2649\u201360.","journal-title":"J Thorac Dis"},{"key":"3842_CR39","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/j.athoracsur.2017.07.024","volume":"104","author":"N Chudgar","year":"2017","unstructured":"Chudgar N, Brennan MF, See Tan K, Munhoz RR, D\u2019Angelo SP, Bains MS, et al. Is Repeat Pulmonary Metastasectomy Indicated for Soft Tissue Sarcoma? Ann Thorac Surg. 2017;104:1837\u201345.","journal-title":"Ann Thorac Surg"},{"issue":"5","key":"3842_CR40","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.ejca.2015.01.061","volume":"51","author":"P Navarria","year":"2015","unstructured":"Navarria P, Ascolese AM, Cozzi L, Tomatis S, D\u2019Agostino GR, De Rose F, et al. Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma. Eur J Cancer. 2015;51(5):668\u201374.","journal-title":"Eur J Cancer"},{"issue":"2","key":"3842_CR41","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/1357714021000022168","volume":"6","author":"JM Kane","year":"2002","unstructured":"Kane JM, Finley JW, Driscoll D, Kraybill WG, Gibbs JF. The treatment and outcome of patients with soft tissue sarcomas and synchronous metastases. Sarcoma. 2002;6(2):69\u201373.","journal-title":"Sarcoma"},{"issue":"12","key":"3842_CR42","doi-asserted-by":"publisher","first-page":"7873","DOI":"10.1245\/s10434-021-09654-z","volume":"28","author":"CJ Swallow","year":"2021","unstructured":"Swallow CJ, Strauss DC, Bonvalot S, Rutkowski P, Desai A, Gladdy RA, et al. Transatlantic Australasian RPS Working Group (TARPSWG). Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group. Ann Surg Oncol. 2021;28(12):7873\u201388.","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"3842_CR43","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/S1470-2045(20)30446-0","volume":"21","author":"S Bonvalot","year":"2020","unstructured":"Bonvalot S, Gronchi A, Le P\u00e9choux C, Swallow CJ, Strauss D, Meeus P, et al. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21(10):1366\u201377.","journal-title":"Lancet Oncol"},{"issue":"1","key":"3842_CR44","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ygyno.2017.02.012","volume":"145","author":"BL Seagle","year":"2017","unstructured":"Seagle BL, Sobecki-Rausch J, Strohl AE, Shilpi A, Grace A, Shahabi S. Prognosis and treatment of uterine leiomyosarcoma: A National Cancer Database study. Gynecol Oncol. 2017;145(1):61\u201370.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"3842_CR45","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.ejca.2008.01.019","volume":"44","author":"NS Reed","year":"2008","unstructured":"Reed NS, Mangioni C, Malmstr\u00f6m H, Scarfone G, Poveda A, Pecorelli S, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer. 2008;44(6):808\u201318.","journal-title":"Eur J Cancer"},{"issue":"8","key":"3842_CR46","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1001\/jamaoncol.2024.1805","volume":"10","author":"B Kasper","year":"2024","unstructured":"Kasper B, Baldini EH, Bonvalot S, Callegaro D, Cardona K, Colombo C, et al. Desmoid Tumor Working Group. Current management of desmoid tumors: a review. JAMA Oncol. 2024;10(8):1121\u20138.","journal-title":"JAMA Oncol"},{"issue":"10","key":"3842_CR47","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1056\/NEJMoa2210140","volume":"388","author":"M Gounder","year":"2023","unstructured":"Gounder M, Ratan R, Alcindor T, Sch\u00f6ffski P, van der Graaf WT, Wilky BA, et al. Nirogacestat, a gamma-secretase inhibitor for desmoid tumors. N Engl J Med. 2023;388(10):898\u2013912.","journal-title":"N Engl J Med"},{"issue":"10","key":"3842_CR48","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa2303383","volume":"389","author":"AP Chen","year":"2023","unstructured":"Chen AP, Sharon E, O\u2019Sullivan-Coyne G, Moore N, Foster JC, Hu JS, et al. Atezolizumab for Advanced Alveolar Soft Part Sarcoma. N Engl J Med. 2023;389(10):911\u201321.","journal-title":"N Engl J Med"},{"issue":"1","key":"3842_CR49","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S1470-2045(18)30676-4","volume":"20","author":"J Martin-Broto","year":"2019","unstructured":"Martin-Broto J, Stacchiotti S, Lopez-Pousa A, Redondo A, Bernabeu D, de Alava E, et al. Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2019;20(1):134\u201344.","journal-title":"Lancet Oncol"},{"key":"3842_CR50","doi-asserted-by":"publisher","first-page":"102259","DOI":"10.1016\/j.ctrv.2021.102259","volume":"99","author":"J Mart\u00ednez-Trufero","year":"2021","unstructured":"Mart\u00ednez-Trufero J, Cruz Jurado J, G\u00f3mez-Mateo MC, Bernabeu D, Flor\u00eda LJ, Lavernia J, et al. Uncommon and peculiar soft tissue sarcomas: multidisciplinary review and practical recommendations for diagnosis and treatment. Spanish group for Sarcoma research (GEIS - GROUP). Part I Cancer Treat Rev. 2021;99:102259.","journal-title":"Part I. Cancer Treat Rev."}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03842-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-024-03842-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03842-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T17:02:18Z","timestamp":1744736538000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-024-03842-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":50,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["3842"],"URL":"https:\/\/doi.org\/10.1007\/s12094-024-03842-5","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]},"assertion":[{"value":"20 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CS\n                      reports Advisory Board\n                      from\u00a0IDRX\n                      \u00a0and\n                      NewBay;\n                      Advisory Board\u2014Speaker\u2014Grant\n                      from\u00a0Deciphera and Blueprint and\n                      Speaker\n                      from\u00a0Pharmamar and Roche.\n                      MA\n                      reports Speaker\u2014Grant\n                      from\u00a0Lilly, Astrazeneca and Roche and Grant from Takeda.\n                      NH\n                      Advisory Board\u2014Speaker\u2014Grant\u2014Other\n                      from\u00a0PharmaMar\n                      \u00a0and\n                      Deciphera;\n                      Speaker\n                      from\u00a0Asofarma and\n                      Other\n                      from\u00a0Immunome, INBRX, COGENT, LIXTE, Synox, Abbisko, Lilly, Boehringer and Cebiotex.\n                      MASG\n                      reports Advisory Board\u2014Speaker\u2014Grant fromRoche Farma; Speaker\u2014Grant from Pzifer; Grant from Astra Zeneca and PharmaMar and Speaker from Deciphera.\n                      JMT\n                      reports Advisory Board\u2014Other from\u00a0Pharmamar, GSK and Boehringer; Advisory Board\u2014Speaker from\u00a0Eisai and Deciphera; Speaker from\u00a0Roche and Merck and Other from\u00a0MSD.\n                      JMG, RSM, APR, AMD and ICG\n                      have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The current study has been performed inaccordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"For this type of study, no informed consent is required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}